Epizyme Announces Date of Third Quarter 2017 Financial Results
October 25, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Closing of Public Offering of Common Stock
September 19, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the closing of its...
Epizyme Announces Pricing of Public Offering of Common Stock
September 14, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the pricing of an...
Epizyme Announces Proposed Public Offering of Common Stock
September 13, 2017 16:01 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it intends to...
Epizyme to Participate in Upcoming Investor Conferences
August 30, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Leadership Transition for Finance Organization
August 15, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced a leadership...
Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
August 04, 2017 06:30 ET
|
Epizyme, Inc.
Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors Expansion of Collaborations to Accelerate Investigation of Tazemetostat Across Multiple...
US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
August 01, 2017 06:30 ET
|
Epizyme, Inc.
THE WOODLANDS, Texas and CAMBRIDGE, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US...
Epizyme Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
July 31, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
July 24, 2017 16:05 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the National...